Supplemental digital content 2.pdf-Summary of the characteristics of all included studies on treatment for metastatic uveal melanoma Intervention Study Publication year Study design Number of uveal melanoma patients Number of first-line treatments (%) Number of surgically treated patients (%) Median time from metastasis to treatment months, (range) OS definition Median OS, published Kaplan-Meier estimate months, (95% CI) Median OS, digitised Kaplan-Meier estimate months, (95% CI) Region(s) Conventional chemotherapy (CHT) Dacarbazine Carling [1] 2015 Retrospective CCS * Thirteen patients received dacarbacine, five received temozolomide with or without interferon, five received fotemustine, two received carboplatin/dacarbacine/interferon-alpha/interleukin-2. Because of multiple different therapies the patients were included in the conventional chemotherapy group but could they could not be organised under a specific chemotherapy agent. * The Kaplan-Meier graph did not have steps and possibly because of resultant difficulty in digitizing the median survivals differ. † Median survival is 12 months when calculated from Table 1; the reported median survival of 15 months appears to correspond to mean survival [(7+8+8+12+16+18+20+29)/8=15 months]. ‡ The reported median survival of 18 months appears to be arithmetically calculated and not a Kaplan-Meier estimate. § Reported for all patients, not specifically for uveal melanoma patients.

Supplemental Digital Content is available in the text.

No abstract